Mizollen (Mizolastine)

Mizolastine works by selectively antagonising peripheral H1 receptors. By blocking histamine from binding to these receptors, it prevents the cascade that leads to vasodilation, increased vascular permeability and sensory nerve activation, thereby mitigating the typical signs of an allergic reaction.

The appropriate dose of Mizollen is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Dosage recommendations are provided in the product’s prescribing information and should be followed exactly as instructed.

Safety data for mizolastine in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Mizollen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with first‑generation antihistamines, mizolastine offers similar efficacy for allergic symptoms but with a lower propensity for sedation and anticholinergic effects. Within the second‑generation class, its potency and duration of action are comparable to agents such as cetirizine and fexofenadine, while maintaining a favorable safety profile.

Mizollen should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Mizollen is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure optimal absorption and effectiveness.

The most serious adverse reactions associated with mizolastine include severe skin reactions such as Stevens‑Johnson syndrome, angioedema that can affect breathing, and rare cases of anaphylaxis. Any signs of rash, swelling of the face or throat, or difficulty breathing require immediate medical attention.

Mizollen is contraindicated in individuals with known hypersensitivity to mizolastine or any of the tablet’s excipients. Caution is advised for patients with severe hepatic impairment, and it should not be used in children younger than 12 years unless specifically directed by a qualified clinician.